Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth but faces market and regulatory hurdles in Q3 2024.

Apellis said it was expecting the CHMP’s decision after the panel indicated it was minded to reject the application in December and added that it would seek “immediate re-examination” of the ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Nov. 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals ... Received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) in September 2024. Expect regulatory decisions ...

Nov. 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals ... opinion from the Committee for Medicinal Products for Human Use (CHMP) in September 2024. Expect regulatory decisions in the U.K ...

We were disappointed with the negative CHMP opinion despite multiple analyses ... paradigm for patients with C3G and IC-MPGN. At Apellis, we have spent the last two decades investigating C3 ...